Drug intelligence / Profile preview

Nanjing Univ. of Chinese Medicine HDAC8 compound probe 19

Development stage: Unknown
Lead developer: Nanjing University of Chinese Medicine

Overview

Nanjing Univ. of Chinese Medicine HDAC8 compound probe 19: sourced facts only. name: "Probe 19 was selected for cell imaging and it showed significantly enhanced fluorescence only after binding into the cavity of HDAC8 in SH-SY5Y and MDA-MB-231 tumor cells." [PMID:35661851]; target: "Probe 19 was selected for cell imaging and it showed significantly enhanced fluorescence only after binding into the cavity of HDAC8 in SH-SY5Y and MDA-MB-231 tumor cells." [PMID:35661851]; developer: "School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China." [PMID:35661851]

Targets

HDAC8 (Histone Deacetylase 8)

Beyond the preview

Go deeper on Nanjing Univ. of Chinese Medicine HDAC8 compound probe 19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Univ. of Chinese Medicine HDAC8 compound probe 19.